Sage Therapeutics Quote, Financials, Valuation and Earnings

Sage Therapeutics Price Quote

+0.10 (+1.32%)
(Updated: March 25, 2023 at 5:24 AM ET)

Sage Therapeutics Key Stats

Sage Therapeutics (SAGE) is a Buy

Day range:
$41.51 - $43.04
52-week range:
$27.36 - $49.56
Dividend yield:
P/E ratio:
P/S ratio:
P/B ratio:

Avg. volume:
1-year change:
Market cap:

How Much Does Sage Therapeutics Make?

Is Sage Therapeutics Growing As A Company?

  • What Is Sage Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 0.74%
  • What Is Sage Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Sage Therapeutics Stock Price Performance

What Is Sage Therapeutics 52-Week High & Low?

Sage Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Sage Therapeutics?

  • How Much Debt Does Sage Therapeutics Have?
    Total long term debt quarterly is $0
  • How Much Cash Does Sage Therapeutics Have?
    Cash and short term investments quarterly total is $1.3B
  • What Is Sage Therapeutics’s Book Value Per Share?
    Book value per share is 21.05

Is Sage Therapeutics Cash Flow Positive?

  • What Is SAGE Cash Flow From Operations?
    Cash flow from operations (TTM) is -$460M
  • What Is Sage Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $3.1M
  • What Is Sage Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $325.4M

Sage Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    SAGE return on invested capital is -35.59%
  • What Is Sage Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -33.4%
  • What Is SAGE Return On Equity?
    ROE is a measure of profitability and is -35.59%

Sage Therapeutics Earnings Date & Stock Price

Sage Therapeutics Competitors

  • Who Are Sage Therapeutics's Competitors?
    Below is a list of companies who compete with Sage Therapeutics or are related in some way:
    • Align Technology Inc (ALGN)
    • Biogen Inc (BIIB)
    • Boston Scientific Corp (BSX)
    • QuidelOrtho Corp (QDEL)
    • Prometheus Biosciences Inc (RXDX)

Sage Therapeutics Dividend Yield

Data Unavailable

Sage Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -4.44%
Revenue: 74.48% 47.65%

Analyst Recommendations

Buy Recommendations: 6
Hold Recommendations: 12
Sell Recommendations: 0
Price Target: 57.86
Upside from Last Price: 34.83%

Major Shareholders

  • How many SAGE shares are owned by institutional investors?
    93.3M SAGE shares are owned by institutional investors
  • How many SAGE shares are owned by insiders?
    1.1M SAGE shares are owned by insiders